XTalks

JANUARY 28, 2022

Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Immunocore was granted the approval for Kimmtrak several weeks ahead of the scheduled PDUFA date of February 23. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. The post Immunocore gets EU nod for TCR cancer therapy Kimmtrak appeared first on. ” Image by Pexels from Pixabay .

Protein 52

Protein Sales Drugs Trials 52

Drug Discovery World

NOVEMBER 13, 2023

Christopher Rowley, PhD, Principal Research Scientist, Protein Science Pipeline, Immunocore, on: ‘ImmTAC: A high-affinity soluble TCR bispecific platform to target cancers’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

This session will conclude with chairperson’s remarks from Kerry Chester, PhD, Professor, Molecular Medicine, University College London, followed by a presentation on broadening specificity of T-cell receptors for HLA-A*03:01/A*11:01 alloselectivity by Vijaykumar Karuppiah, PhD, Associate Director, Protein Engineering, Immunocore.

Engineer 52

Engineer Antibody Protein In-Vivo 52